Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wisefemy is a branded generic combined oral contraceptive (COC) marketed by Alna Biotech. It consists of a fixed-dose combination of levonorgestrel, a second-generation synthetic progestin, and ethinyl estradiol, a synthetic estrogen. The primary mechanism of action is the suppression of ovulation through the inhibition of the hypothalamic-pituitary-ovarian axis, specifically by reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Additionally, Wisefemy alters the cervical mucus to impede sperm transport and modifies the endometrium to inhibit implantation. It is indicated for the prevention of pregnancy and may also be used for the management of menstrual irregularities and dysmenorrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levonorgestrel + ethinyl estradiol (Alna Biotech).